The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more

Key Takeaways Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential. Strategic advancements in gene editing could expand patient access and drive revenue growth through broader treatment availability.Read more
